Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma
Authors:
Open Access
- 19 August 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 8021
Abstract
Autologous stem cell transplantation (ASCT) after high-dose chemo-therapy (HDCT) is an option of consolidation therapy in patients with AML, lymphoma, or myeloma. Clonal hematopoiesis (CH) is a premalignant state, associated with an increased risk of hematological cancer. The incidence of CH in patients with AML, myeloma, and lymphoma and its effect on the outcome after HDCT/ASCT remain poorly studied. Here we screened 142 patients treated with HDCT/ASCT between 2002 and 2021 at Bern University Hospital for somatic gene mutations in ASXL1, DNMT3A, JAK2, TET2, and TP53. CH-associated somatic gene mutations were detected in 14/31 AML patients (45%), 13/64 myeloma patients (20%), and 9/47 lymphoma patients (19%). Clinical characteristics, treatment modalities, and responses to treatment were similar in patients with and without CH. Patients with CH-associated gene mutations had higher relapse rates and reduced progression free survival, most evident in lymphoma patients (p = 0.007). Overall survival tended to be shorter in lymphoma patients with CH-associated mutations (p = 0.078), whereas this was not observed in AML and myeloma patients. Survival in lymphoma patients with CH was inferior, which may have an impact on post-transplant surveillance strategies in the future. In contrast, survival outcomes were not associated significantly with CH in AML and myeloma patients in our study. Longer follow-ups and larger cohorts will be needed to validate our observations.Keywords
This publication has 23 references indexed in Scilit:
- Clonal hematopoiesis is associated with protection from Alzheimer’s diseaseNature Medicine, 2023
- Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphomaAmerican Journal of Hematology, 2022
- Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular diseaseJournal of Molecular and Cellular Cardiology, 2021
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantNature Communications, 2020
- The EBMT Handbook2019
- Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantationBone Marrow Transplantation, 2018
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyThe Lancet Oncology, 2017
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control studyThe Lancet Oncology, 2017
- BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patientsAnnals of Hematology, 2016
- Age-related mutations associated with clonal hematopoietic expansion and malignanciesNature Medicine, 2014